Seth Harmon's most recent trade in Viridian Therapeutics Inc was a trade of 2,031 Common Stock done at an average price of $30.2 . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.19 per share. | 03 Mar 2026 | 2,031 | 7,850 (0%) | 0% | 30.2 | 61,316 | Common Stock |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 102,850 | 102,850 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 20,550 | 20,550 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 6,267 | 9,881 (0%) | 0% | - | Common Stock | |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 6,267 | 18,801 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.32 per share. | 02 Mar 2026 | 2,091 | 7,790 (0%) | 0% | 29.3 | 61,308 | Common Stock |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 150,407 | 150,407 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Seth Harmon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 25,068 | 25,068 | - | - | Restricted Stock Units |